AB64830

Anti-RED1 antibody

Name: Anti-RED1 antibody (ab64830) | Abcam
Brand: Abcam Limited
SKU: AB64830
Price: 515 USD
Availability: InStock
Rating: 4 (1 reviews)

(1 Review)

(7 Publications)

Rabbit Polyclonal RED1 antibody. Suitable for ELISA, WB, IHC-P, ICC/IF and reacts with Mouse, Human samples. Cited in 7 publications. Immunogen corresponding to Synthetic Peptide within Human ADARB1.

View Alternative Names

ADAR2, DRADA2, RED1, ADARB1, Double-stranded RNA-specific editase 1, RNA-editing deaminase 1, RNA-editing enzyme 1, dsRNA adenosine deaminase

2 Images

Immunocytochemistry/ Immunofluorescence - Anti-RED1 antibody (AB64830)

ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-RED1 antibody (AB64830)

ICC/IF image of ab64830 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab64830, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

Unknown

Western blot - Anti-RED1 antibody (AB64830)

All lanes:

Western blot - Anti-RED1 antibody (ab64830) at 1/500 dilution

Lane 1:

HepG2 cell extract (5-30 µg total protein)

Lane 2:

HepG2 cell extract (5-30 µg total protein) ) with 5-10 µg of the immunising peptide

Predicted band size: 81 kDa

Observed band size: 81 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Human, Mouse

Applications

ICC/IF, WB, IHC-P, ELISA

applications

Immunogen

Synthetic Peptide within Human ADARB1. The exact immunogen used to generate this antibody is proprietary information.

P78563

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/1000", "WB-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1-5 µg/mL", "ICCIF-species-notes": "" }, "Mouse": { "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "ELISA-species-checked": "predicted", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Storage buffer

pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Storage information

Stable for 12 months at -20°C

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RED1 also known as ADARB1 is a protein involved in RNA editing. It weighs approximately 73 kDa. RED1 mainly expresses itself in the central nervous system but also appears in other tissues. This protein modifies RNA molecules by catalyzing the conversion of adenosine to inosine which can alter the coding potential and metabolism of the RNA it acts upon.

Biological function summary

The protein RED1 functions within RNA editing complexes. It co-operates with other proteins like ADAR1 to carry out its editing role. In particular RED1 affects the regulation of gene expression influencing neuronal function and development in the brain. Through its editing capabilities the protein contributes to the diversity and stability of RNA transcripts.

Pathways

RED1 plays a role in neurotransmission and neurodevelopment pathways. It interacts with other editing proteins in the ADAR family to ensure proper RNA sequence modifications critical for brain function. The editing process that RED1 participates in impacts synaptic transmission important for neuronal communication and neural network formation.

The protein RED1 is associated with neurological disorders. Changes in RED1 expression or mutations can link to conditions such as epilepsy and schizophrenia. Aberrations in RNA editing performed by RED1 might lead to the dysfunction of proteins involved in neuronal signaling. It also connects with proteins like ADAR2 influencing the pathological progress of these conditions.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include : bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.. Isoform 1. Has a lower catalytic activity than isoform 2.. Isoform 2. Has a higher catalytic activity than isoform 1.

See full target information ADARB1

style

left-column

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

Molecular therapy. Nucleic acids 21:932-953 PubMed32814251

2020

Adenosine-to-Inosine Editing of Vasoactive MicroRNAs Alters Their Targetome and Function in Ischemia.

Applications

Unspecified application

Species

Unspecified reactive species

Reginald V C T van der Kwast,Laura Parma,M Leontien van der Bent,Eva van Ingen,Fabiana Baganha,Hendrika A B Peters,Eveline A C Goossens,Karin H Simons,Meindert Palmen,Margreet R de Vries,Paul H A Quax,A Yaël Nossent

Nucleic acids research 46:7379-7395 PubMed29992293

2018

SRSF9 selectively represses ADAR2-mediated editing of brain-specific sites in primates.

Applications

Unspecified application

Species

Unspecified reactive species

Raghuvaran Shanmugam,Fan Zhang,Harini Srinivasan,John Lalith Charles Richard,Kaiwen I Liu,Xiujun Zhang,Cheok Wei A Woo,Zi Hao M Chua,Jan Paul Buschdorf,Michael J Meaney,Meng How Tan

Nucleic acids research 46:7323-7338 PubMed29733375

2018

Tissue-selective restriction of RNA editing of CaV1.3 by splicing factor SRSF9.

Applications

Unspecified application

Species

Unspecified reactive species

Hua Huang,Katannya Kapeli,Wenhao Jin,Yuk Peng Wong,Thiruma Valavan Arumugam,Joanne Huifen Koh,Sumitra Srimasorn,Karthik Mallilankaraman,John Jia En Chua,Gene W Yeo,Tuck Wah Soong

Genes 9: PubMed29419780

2018

Differential Enzymatic Activity of Rat ADAR2 Splicing Variants Is Due to Altered Capability to Interact with RNA in the Deaminase Domain.

Applications

Unspecified application

Species

Unspecified reactive species

Alice Filippini,Daniela Bonini,Edoardo Giacopuzzi,Luca La Via,Fabrizio Gangemi,Marina Colombi,Alessandro Barbon

Molecular cell 69:126-135.e6 PubMed29304330

2018

N-Methyladenosines Modulate A-to-I RNA Editing.

Applications

Unspecified application

Species

Unspecified reactive species

Jian-Feng Xiang,Qin Yang,Chu-Xiao Liu,Man Wu,Ling-Ling Chen,Li Yang

RNA biology 14:1580-1591 PubMed28640668

2017

Absence of the Fragile X Mental Retardation Protein results in defects of RNA editing of neuronal mRNAs in mouse.

Applications

Unspecified application

Species

Unspecified reactive species

Alice Filippini,Daniela Bonini,Caroline Lacoux,Laura Pacini,Maria Zingariello,Laura Sancillo,Daniela Bosisio,Valentina Salvi,Jessica Mingardi,Luca La Via,Francesca Zalfa,Claudia Bagni,Alessandro Barbon

PloS one 9:e91288 PubMed24608178

2014

Down-regulation of the RNA editing enzyme ADAR2 contributes to RGC death in a mouse model of glaucoma.

Applications

IHC-P

Species

Mouse

Ai Ling Wang,Reed C Carroll,Scott Nawy

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-RED1 antibody

Immunocytochemistry/ Immunofluorescence - Anti-RED1 antibody (AB64830)

Western blot - Anti-RED1 antibody (AB64830)

Key facts

Host species

Clonality

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (7)

Alternative Products

Primary Antibodies

Complementary Products

Primary Antibodies

Primary Antibodies

Assay Kits

Primary Antibodies

Product promise